shutterstock_1349458007_pavel_kapysh
Pavel Kapysh / Shutterstock.com
5 December 2019AmericasSarah Morgan

Astellas doubles down on gene therapy with $3bn Audentes deal

Astellas is set to buy US-based Audentes Therapeutics for approximately $3 billion, as the Japanese pharmaceutical company looks to boost its gene therapy expertise.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia-Pacific
15 August 2018   Japan-based Astellas Pharma has acquired Quethera, a UK-headquartered gene therapy company focused on developing treatments for ocular disorders.
Americas
25 February 2019   Switzerland-based Roche will buy gene therapy company Spark Therapeutics in a $4.3 billion deal.

More on this story

Asia-Pacific
15 August 2018   Japan-based Astellas Pharma has acquired Quethera, a UK-headquartered gene therapy company focused on developing treatments for ocular disorders.
Americas
25 February 2019   Switzerland-based Roche will buy gene therapy company Spark Therapeutics in a $4.3 billion deal.

More on this story

Asia-Pacific
15 August 2018   Japan-based Astellas Pharma has acquired Quethera, a UK-headquartered gene therapy company focused on developing treatments for ocular disorders.
Americas
25 February 2019   Switzerland-based Roche will buy gene therapy company Spark Therapeutics in a $4.3 billion deal.